Dmitry Balyasny’s Solid Biosciences SLDB Stock Holding History

Dmitry Balyasny’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Hold	178,253	–	–	﹤0.01%	1883
2026 Q1	$1.2M	Sell	178,253 -182,684	-51%	-$1.17M	﹤0.01%	2003
2025 Q4	$2.04M	Sell	360,937 -371,671	-51%	-$2.01M	﹤0.01%	1856
2025 Q3	$4.52M	Buy	732,608 +245,485	+50%	+$1.44M	0.01%	1412
2025 Q2	$2.37M	Sell	487,123 -140,151	-22%	-$495K	﹤0.01%	1652
2025 Q1	$2.32M	Buy	+627,274	New	+$2.69M	﹤0.01%	1639
2024 Q4	–	Sell	-236,942	Closed	-$1.65M	–	3221
2024 Q3	$1.65M	Buy	+236,942	New	+$1.92M	﹤0.01%	1752
2024 Q2	–	Sell	-23,525	Closed	-$313K	–	3062
2024 Q1	$313K	Buy	+23,525	New	+$220K	﹤0.01%	2242
2022 Q4	–	Sell	-1,982	Closed	-$14K	–	3197
2022 Q3	$14K	Buy	1,982 +1,209	+156%	+$12.2K	﹤0.01%	2611
2022 Q2	$7K	Buy	+773	New	+$8.03K	﹤0.01%	2623
2018 Q3	–	Sell	-8,023	Closed	-$4.29M	–	2002
2018 Q2	$4.29M	Buy	+8,023	New	+$2.47M	0.02%	711

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's SLDB Position: Q2 2026 in Review

Dmitry Balyasny held its Solid Biosciences (SLDB) position steady in Q2 2026 at 178,253 shares worth $1.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

Dmitry Balyasny first reported a position in SLDB in Q2 2018 and has held it in 11 quarters since. The position peaked at $4.52M in Q3 2025. 155 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Dmitry Balyasny held 178,253 shares of Solid Biosciences worth $1.78M as of Q2 2026.
Dmitry Balyasny left its Solid Biosciences share count unchanged in Q2 2026.
Solid Biosciences made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1883 holding.
Dmitry Balyasny first reported a position in Solid Biosciences in Q2 2018 and has held it in 11 quarters since.
Dmitry Balyasny's Solid Biosciences position peaked at $4.52M in Q3 2025.
155 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.